By Editor , 4 November 2026
Verismo's SynKIR-110 Beats Single-Chain CAR T in Preclinical Study

Philadelphia – November 03, 2026 -- Verismo Therapeutics' SynKIR-110 achieved the fastest tumor control among three CAR T designs in preclinical mesothelioma models while producing roughly 10-fold less IFNγ and 30-fold less TNFα and IL-2 than a CD28-based single-chain CAR T.

The company will present the data at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix (Abstract 253). The study compared SynKIR-110 with CD28- and 4-1BB-based single-chain CAR T cells in mesothelioma xenograft models.

By Editor , 4 November 2026
US, DRC Launch Joint Governance of 42,000 MW Grand Inga Project

Washington – November 03, 2026 -- The United States and the Democratic Republic of Congo have launched joint governance of Grand Inga, a Congo River hydropower complex with an estimated 42,000 megawatts of potential capacity, according to a statement distributed on behalf of the Congolese government. The inaugural Grand Inga Coordination and Governance Committee met at the World Bank offices in Paris.

By Editor , 4 November 2026
Cardiol Opens US$75M ATM Program With Jefferies for Heart Drugs

TORONTO – November 03, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) has entered into an at-the-market program that lets it sell up to US$75 million of common shares through Jefferies LLC to fund late-stage cardiac drug development.

Cardiol restricts ATM share sales to U.S. trading venues

Shares will be sold in ordinary brokers' transactions on the Nasdaq Capital Market or other U.S. trading markets at prevailing market prices. No shares will be sold through the Toronto Stock Exchange or elsewhere in Canada.

By Editor , 4 November 2026
APTIM Names Ex-V2X CEO Chuck Prow Chief Executive and Chairman

Baton Rouge – November 03, 2026 -- APTIM has appointed Chuck Prow, former CEO of defense infrastructure firm V2X, as Chief Executive Officer and Chairman effective November 9, 2026. He succeeds Mark Fallon, who is stepping down from both roles to pursue other ventures.

By Editor , 4 November 2026
OnchainTA to Supply Tokenized Securities Services to Transfer Online

FULLERTON – – November 03, 2026 -- Transfer Online, Inc. (TOL), an SEC-registered transfer agent operating since 1999, plans to begin offering tokenization to its clients early next year under a signed partnership with OnchainTA, the SEC-registered Digital Transfer Agent owned by Akemona, Inc. Commercial terms were not disclosed.

By Editor , 4 November 2026
ACT for ALS Reauthorized: Up to $500M for Research and Access

WASHINGTON – November 03, 2026 -- The President has signed the ACT for ALS reauthorization bill into law, extending the program for five years and committing up to an additional $500 million to ALS research infrastructure and investigational treatment access, according to patient advocacy group I AM ALS.

By Editor , 4 November 2026
Medtronic RDN Study Cuts Office BP 18.2 mmHg; FDA Updates Label

GALWAY – November 03, 2026 -- Medtronic's Symplicity Spyral renal denervation (RDN) system cut office systolic blood pressure by 18.2 mmHg at six months in the SPYRAL AFFIRM post-approval study, with no increase in antihypertensive medication. The company also received U.S. FDA approval to update the device's labeling with additional clinical data.

By Editor , 4 November 2026
Atlas-SSI Acquires Linita to Expand Hydropower Equipment Portfolio

Monticello, Mississippi – November 03, 2026 -- Atlas-SSI, Inc. has acquired Linita Design & Manufacturing, a custom hydro-mechanical equipment maker with more than 35 years of experience, to broaden its water control and debris management offering for dams and hydropower facilities. The announcement did not include financial terms.

By Editor , 4 November 2026

Fort Lauderdale – November 03, 2026 -- Cloud Software Group Holdings, Inc. raised the cash consideration in its tender offer for its 9.00% Senior Secured Second Lien Notes due 2029 to $1,022.50 per $1,000 principal amount, up from $1,017.50.

Consideration rises $5.00 per $1,000 of notes tendered

The increase lifts the offered price to 2.25% above par, from 1.75% previously. Holders whose notes are accepted will also receive accrued and unpaid interest, calculated from the last interest payment date up to, but excluding, the settlement date.